In December 2019, Dr Vinod Balachandran and his team had just recruited the first patients for an exciting clinical trial that was happening in New York. It was to test a new type of vaccine for pancreatic cancer. The vaccine, made from a molecule called messenger ribonucleic acid (mRNA), was designed to prime the patients’ immune systems to attack their cancer cells, but before the trial could get into full swing, disaster struck. A novel virus, discovered in China, was silently spreading around the globe. Three months later, New York was in lockdown.
With a lot of routine cancer treatment paused, trial participants were understandably nervous. “Patients didn’t want to travel to New York,” says Balachandran, who is based in the city’s Memorial Sloan Kettering Cancer Center. Then there were logistical issues. Biopsy samples taken from the participants had to be sent to a biotech company in Germany for analysis, and the vaccine, which was then tailor-made for each patient, had to be promptly sent back. With many routine flights grounded, it seemed like a tall order, but perhaps the biggest hurdle facing the trial was the fact that the German biotech company they were working with, BioNTech, now found itself embroiled in a race to produce the world’s first vaccine for COVID-19.
In the year that followed, BioNTech collaborated with another company, Pfizer, to produce more than 20 candidate COVID-19 vaccines, all made from mRNA, including the one that went on to be given to hundreds of millions of people. It’s fair to say that 2020 was a busy year for BioNTech, so you’d be forgiven for presuming that the trial for the cancer vaccines fell by the wayside, but that wasn’t the case.
BLESSING IN DISGUISE
This story is from the New Year 2022 edition of BBC Science Focus.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the New Year 2022 edition of BBC Science Focus.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
5 SIMPLE WAYS TO RECLAIM YOUR ATTENTION
Primed for constant interruptions, your brain is now distracting itself, says science. It's time to break the cycle and retrain your focus
GOING ROGUE
Some planets are stuck following the same orbital paths their entire lives. Others break free to wander alone through the vast, empty darkness of interstellar space and there's a lot more of them than you might think
BED BUGS VS THE WORLD
When bloodthirsty bed bugs made headlines for infesting Paris Fashion Week in 2023, it shone a spotlight on a problem that's been making experts itch for decades: the arms race going on between bed bugs and humans. Now, with the 2024 Summer Olympics fast approaching, the stakes are higher than ever
THE EYES THAT WATCH THE SKY
When it launches in 2026, the Copernicus programme's Anthropogenic Carbon Dioxide Monitoring satellite will give us a new window on to Earth's atmosphere... And how we're altering it
TIME-RESTRICTED EATING LINKED TO HIGHER RISK OF CARDIOVASCULAR DEATH
Skipping breakfast might not be so good for your health, after all
INSIDE THE PROJECT TO SCAN THOUSANDS OF RARE SPECIMENS
A major collaborative project has created 3D reconstructions of previously locked away museum specimens
VIDEO IS FIRST EVIDENCE OF AN ORCA KILLING A GREAT WHITE
Tourists sailing off the South African coast film a never-before-seen event: a lone orca attacking a 2.5m shark
AI REVEALS PROSTATE CANCER IS NOT JUST ONE DISEASE
DNA analysis carried out by artificial intelligence has helped scientists make a discovery that could revolutionise future treatment
MYSTERIOUS WAVES DETECTED IN JUPITER'S CORE
Scientists hope unusual fluctuations in the gas giant's magnetic field might reveal what's inside
MINI ORGANS GROWN FROM UNBORN BABIES MARK A BREAKTHROUGH IN PRENATAL MEDICINE
A new technique could allow congenital conditions to be diagnosed and treated before birth